Jersey City, New Jersey, September 15, 2026
Organon has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Supplemental New Drug Application (sNDA) for MIUDELLA, a hormone-free intrauterine device designed to provide contraception. The regulatory acceptance represents an important milestone for Organon’s women’s health portfolio and could expand access to a non-hormonal contraceptive option in the United States. MIUDELLA uses copper rather than hormones to provide contraceptive protection and is intended for women seeking a long-acting reversible contraceptive option. The FDA’s acceptance means the agency has formally agreed to review the supplemental application, although it does not constitute approval of the proposed changes or indication.
FDA Accepts MIUDELLA Supplemental Application
The FDA’s acceptance of the MIUDELLA sNDA begins the agency’s formal review process. Organon is seeking regulatory action concerning the hormone-free intrauterine device, which is designed to provide long-term contraception without releasing hormones into the body. The application builds on the product’s existing regulatory pathway and reflects Organon’s continued focus on developing and expanding contraceptive choices for women. Unlike hormonal intrauterine systems, MIUDELLA is copper-based, using the contraceptive properties of copper to prevent pregnancy. Copper IUDs have been used as long-acting reversible contraception for decades, providing an option for individuals who prefer to avoid hormonal contraceptive methods. The device is placed inside the uterus by a trained healthcare professional and is designed to provide contraception over an extended period. The FDA’s acceptance for review is an important regulatory step, but it is important to distinguish application acceptance from FDA approval. The agency will evaluate the information contained in the supplemental application before making a regulatory decision. Organon will continue to work with the FDA throughout the review process.
Hormone-Free Contraception Supports Women’s Health
The development of hormone-free contraception addresses an important area of interest within women’s healthcare. While hormonal contraceptives are widely used and effective, some women may prefer non-hormonal options because of personal preferences, previous experiences with hormonal methods, or a desire to use a contraceptive approach that does not involve hormonal exposure. Long-acting reversible contraceptives such as IUDs are considered important tools in modern reproductive healthcare because they can provide highly effective contraception without requiring daily adherence. A copper IUD can remain in place for an extended period while offering reversible contraception, meaning fertility can return after removal. MIUDELLA’s hormone-free design therefore gives healthcare professionals another potential option to discuss with patients when considering long-acting contraceptive methods. Organon’s focus on women’s health places the product within a broader strategy aimed at addressing reproductive-health needs through both pharmaceutical and device-based solutions.
Advertisement
Organon Advances Women’s Health Portfolio
The regulatory milestone strengthens Organon’s presence in the women’s health market, an area in which the company has developed a broad portfolio of contraceptive and reproductive-health products. Organon has emphasized the importance of expanding access to reproductive-health options and providing women with choices that can better align with their individual needs. The FDA review of MIUDELLA could provide an opportunity to further evaluate the product’s labeling and regulatory status in the United States. The eventual outcome will depend on the FDA’s assessment of the supplemental application and supporting evidence. Until the agency reaches a decision, MIUDELLA’s regulatory status should not be interpreted as confirmation of any new indication or labeling change. The announcement also highlights the increasingly diverse landscape of contraceptive technology, where pharmaceutical companies are developing products that combine medical-device technology with established contraceptive mechanisms. Hormone-free approaches remain an important component of this landscape, particularly for women seeking alternatives to hormonal contraception. For cGxP.wire readers, Organon’s announcement represents a significant regulatory and women’s-health development, demonstrating how established contraceptive technologies continue to evolve through new product development and regulatory review. The FDA’s evaluation of the MIUDELLA supplemental application will be closely watched as Organon seeks to advance its hormone-free intrauterine contraceptive offering in the U.S. market.
Source: Organon press release
